To explore the interest and barriers in the adoption of next-generation blood products (NGBPs).
Conducted a survey on familiarity and perceptions regarding NGBPs.
Analyzed responses to identify key drivers and barriers for adoption.
Assessed the role of regulatory licensing in NGBP familiarity.
Low familiarity with NGBPs attributed to insufficient regulatory licensing.
Cost and clinical value are significant considerations for implementation.
Health economic factors influence adoption decisions.
Abstract
The low familiarity with NGBPs is likely due to the lack of broad regulatory licensing of these products. Cost, clinical value, and health economic considerations will be key to implementing these products.